deferoxamine ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
792 70-51-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • deferoxamine
  • deferoxamine mesylate
  • deferoxamin
  • desferrioxamine
  • desferrioxamine mesilate
  • deferoxamine mesilate
  • desferrioxamine mesylate
Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
  • Molecular weight: 560.69
  • Formula: C25H48N6O8
  • CLOGP: -0.18
  • LIPINSKI: 3
  • HAC: 14
  • HDO: 6
  • TPSA: 205.84
  • ALOGS: -3.75
  • ROTB: 23

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
MRTD (Maximum Recommended Therapeutic Daily Dose) 178.35 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 5 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 1.35 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 8.33 mL/min/kg Lombardo F, Berellini G, Obach RS
t_half (Half-life) 3.05 hours Lombardo F, Berellini G, Obach RS
S (Water solubility) 50 mg/mL Bocci G, Oprea TI, Benet LZ
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Bocci G, Oprea TI, Benet LZ

Approvals:

DateAgencyCompanyOrphan
April 1, 1968 FDA NOVARTIS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Serum ferritin increased 228.42 22.88 51 2170 6131 63480670
Laryngitis fungal 88.90 22.88 13 2208 134 63486667
Sickle cell anaemia with crisis 71.43 22.88 20 2201 5983 63480818
Mucormycosis 70.40 22.88 17 2204 2854 63483947
Bacterial sepsis 50.81 22.88 14 2207 3944 63482857
Liver iron concentration increased 41.53 22.88 5 2216 8 63486793
Haemoglobin decreased 37.78 22.88 35 2186 145450 63341351
Iron overload 36.43 22.88 8 2213 883 63485918
Haemosiderosis 34.19 22.88 6 2215 206 63486595
Infective chondritis 30.61 22.88 4 2217 16 63486785
Blood creatinine increased 30.59 22.88 25 2196 87819 63398982
Transplant failure 26.93 22.88 7 2214 1578 63485223
Caesarean section 24.66 22.88 12 2209 17020 63469781
Maculopathy 24.47 22.88 7 2214 2255 63484546
Injection site abscess 23.83 22.88 6 2215 1192 63485609
Thalassaemia beta 23.63 22.88 3 2218 9 63486792
Haemochromatosis 23.14 22.88 5 2216 511 63486290
Agranulocytosis 22.93 22.88 13 2208 25121 63461680

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Serum ferritin increased 173.12 22.21 45 2003 6101 34948782
Blood iron increased 37.47 22.21 9 2039 877 34954006
Spinal X-ray abnormal 34.98 22.21 4 2044 0 34954883
Liver iron concentration increased 31.32 22.21 4 2044 6 34954877
Visual acuity reduced 30.25 22.21 16 2032 16133 34938750
Iron overload 29.13 22.21 8 2040 1325 34953558
Blood creatinine increased 27.97 22.21 31 2017 94945 34859938
Mucormycosis 23.95 22.21 10 2038 5932 34948951
Haemoglobin decreased 23.52 22.21 32 2016 120740 34834143
Myelodysplastic syndrome 22.46 22.21 14 2034 19194 34935689

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Serum ferritin increased 295.06 22.16 71 3299 9776 79731242
Fundoscopy abnormal 140.23 22.16 18 3352 47 79740971
Mucormycosis 81.61 22.16 25 3345 8444 79732574
Laryngitis fungal 78.90 22.16 12 3358 134 79740884
Spinal X-ray abnormal 52.87 22.16 7 3363 25 79740993
Visual acuity reduced 51.32 22.16 25 3345 29444 79711574
Liver iron concentration increased 48.94 22.16 6 3364 9 79741009
Sickle cell anaemia with crisis 46.24 22.16 16 3354 7906 79733112
Haemoglobin decreased 44.96 22.16 51 3319 222068 79518950
Iron overload 43.43 22.16 11 3359 1853 79739165
Agranulocytosis 36.29 22.16 23 3347 45007 79696011
Bacterial sepsis 34.50 22.16 13 3357 8185 79732833
Maculopathy 34.41 22.16 10 3360 2815 79738203
Blood creatinine increased 32.01 22.16 36 3334 155021 79585997
Haemochromatosis 31.61 22.16 8 3362 1342 79739676
Myelodysplastic syndrome 30.90 22.16 18 3352 30283 79710735
Blood iron increased 30.12 22.16 8 3362 1622 79739396
Infective chondritis 27.61 22.16 4 3366 31 79740987
Haemosiderosis 27.61 22.16 6 3364 521 79740497
Optic neuropathy 24.12 22.16 8 3362 3476 79737542
Retinopathy 23.25 22.16 8 3362 3883 79737135
Foetal distress syndrome 22.44 22.16 5 3365 487 79740531

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC V03AC01 VARIOUS
ALL OTHER THERAPEUTIC PRODUCTS
ALL OTHER THERAPEUTIC PRODUCTS
Iron chelating agents
FDA MoA N0000000144 Iron Chelating Activity
FDA EPC N0000175522 Iron Chelator
CHEBI has role CHEBI:26672 siderochromes
CHEBI has role CHEBI:38157 iron chelating agents
CHEBI has role CHEBI:173084 ferroptosis inhibitors
MeSH PA D002614 Chelating Agents
MeSH PA D007502 Iron Chelating Agents
MeSH PA D064449 Sequestering Agents
MeSH PA D017262 Siderophores
CHEBI has role CHEBI:50247 antidotes

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Poisoning by iron AND/OR its compounds indication 55381001
Chronic Iron Overload indication




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.38 acidic
pKa2 8.99 acidic
pKa3 9.53 acidic
pKa4 13.04 acidic
pKa5 13.65 acidic
pKa6 10.56 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Hypoxia-inducible factor 1-alpha Transcription factor EC50 4.75 CHEMBL
Deoxyhypusine hydroxylase Enzyme IC50 5.30 CHEMBL

External reference:

IDSource
4019705 VUID
N0000147797 NUI
D01186 KEGG_DRUG
138-14-7 SECONDARY_CAS_RN
3131 RXNORM
4018789 VANDF
4019705 VANDF
C0011145 UMLSCUI
CHEBI:4356 CHEBI
CHEMBL556 ChEMBL_ID
CHEMBL1234 ChEMBL_ID
D003676 MESH_DESCRIPTOR_UI
DB00746 DRUGBANK_ID
1682 INN_ID
J06Y7MXW4D UNII
2973 PUBCHEM_CID
4539 MMSL
46738 MMSL
d01402 MMSL
001089 NDDF
004540 NDDF
372825006 SNOMEDCT_US
387224002 SNOMEDCT_US
70702006 SNOMEDCT_US
KTY PDB_CHEM_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Desferal HUMAN PRESCRIPTION DRUG LABEL 1 0078-0467 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 500 mg INTRAMUSCULAR NDA 31 sections
Desferal HUMAN PRESCRIPTION DRUG LABEL 1 0078-0467 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 500 mg INTRAMUSCULAR NDA 31 sections
Desferal HUMAN PRESCRIPTION DRUG LABEL 1 0078-0467 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 500 mg INTRAMUSCULAR NDA 31 sections
Deferoxamine Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0409-2336 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 500 mg INTRAMUSCULAR ANDA 30 sections
Deferoxamine Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0409-2336 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 500 mg INTRAMUSCULAR ANDA 30 sections
Deferoxamine Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0409-2337 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 2 g INTRAMUSCULAR ANDA 30 sections
Deferoxamine Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0409-2337 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 2 g INTRAMUSCULAR ANDA 30 sections
Deferoxamine mesylate HUMAN PRESCRIPTION DRUG LABEL 1 47781-623 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 500 mg INTRAMUSCULAR ANDA 12 sections
Deferoxamine mesylate HUMAN PRESCRIPTION DRUG LABEL 1 47781-623 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 500 mg INTRAMUSCULAR ANDA 12 sections
Deferoxamine mesylate HUMAN PRESCRIPTION DRUG LABEL 1 47781-624 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 2 g INTRAMUSCULAR ANDA 12 sections
Deferoxamine mesylate HUMAN PRESCRIPTION DRUG LABEL 1 47781-624 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 2 g INTRAMUSCULAR ANDA 12 sections
Deferoxamine mesylate HUMAN PRESCRIPTION DRUG LABEL 1 52609-4504 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 2 g INTRAMUSCULAR ANDA 11 sections
Deferoxamine mesylate HUMAN PRESCRIPTION DRUG LABEL 1 52609-4505 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 500 mg INTRAMUSCULAR ANDA 11 sections
Deferoxamine mesylate HUMAN PRESCRIPTION DRUG LABEL 1 60505-6236 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 500 mg INTRAMUSCULAR ANDA 11 sections
Deferoxamine mesylate HUMAN PRESCRIPTION DRUG LABEL 1 60505-6236 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 500 mg INTRAMUSCULAR ANDA 11 sections
Deferoxamine mesylate HUMAN PRESCRIPTION DRUG LABEL 1 60505-6237 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 2 g INTRAMUSCULAR ANDA 11 sections
Deferoxamine mesylate HUMAN PRESCRIPTION DRUG LABEL 1 60505-6237 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 2 g INTRAMUSCULAR ANDA 11 sections
Deferoxamine mesylate HUMAN PRESCRIPTION DRUG LABEL 1 60505-6238 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 500 mg INTRAMUSCULAR ANDA 12 sections
Deferoxamine Human Prescription Drug Label 1 63323-597 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 95 mg INTRAVENOUS ANDA 17 sections
Deferoxamine Human Prescription Drug Label 1 63323-599 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 95 mg INTRAVENOUS ANDA 17 sections
Deferoxamine mesylate Human Prescription Drug Label 1 68083-172 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 500 mg INTRAMUSCULAR ANDA 24 sections
Deferoxamine mesylate Human Prescription Drug Label 1 68083-172 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 500 mg INTRAMUSCULAR ANDA 24 sections
Deferoxamine mesylate Human Prescription Drug Label 1 68083-173 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 2 g INTRAMUSCULAR ANDA 24 sections
Deferoxamine mesylate Human Prescription Drug Label 1 68083-173 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 2 g INTRAMUSCULAR ANDA 24 sections